Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for th… Read more
Acrux Limited (ARUXF) - Net Assets
Latest net assets as of June 2025: $1.02 Million USD
Based on the latest financial reports, Acrux Limited (ARUXF) has net assets worth $1.02 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.22 Million) and total liabilities ($6.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.02 Million |
| % of Total Assets | 14.16% |
| Annual Growth Rate | -11.61% |
| 5-Year Change | -94.46% |
| 10-Year Change | -97.67% |
| Growth Volatility | 72.62 |
Acrux Limited - Net Assets Trend (2002–2025)
This chart illustrates how Acrux Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Acrux Limited (2002–2025)
The table below shows the annual net assets of Acrux Limited from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $1.02 Million | -68.77% |
| 2024-06-30 | $3.28 Million | -62.33% |
| 2023-06-30 | $8.70 Million | -4.33% |
| 2022-06-30 | $9.09 Million | -50.79% |
| 2021-06-30 | $18.47 Million | +43.75% |
| 2020-06-30 | $12.85 Million | -41.43% |
| 2019-06-30 | $21.94 Million | -26.81% |
| 2018-06-30 | $29.97 Million | -31.77% |
| 2017-06-30 | $43.92 Million | +0.08% |
| 2016-06-30 | $43.89 Million | +8.03% |
| 2015-06-30 | $40.62 Million | -3.40% |
| 2014-06-30 | $42.06 Million | -10.04% |
| 2013-06-30 | $46.75 Million | -11.96% |
| 2012-06-30 | $53.10 Million | +16.17% |
| 2011-06-30 | $45.71 Million | -43.19% |
| 2010-06-30 | $80.47 Million | +157.72% |
| 2009-06-30 | $31.22 Million | -18.07% |
| 2008-06-30 | $38.11 Million | +108.86% |
| 2007-06-30 | $18.25 Million | -11.35% |
| 2006-06-30 | $20.58 Million | -30.18% |
| 2005-06-30 | $29.48 Million | +250.60% |
| 2004-06-30 | $8.41 Million | -27.91% |
| 2003-06-30 | $11.66 Million | -33.29% |
| 2002-06-30 | $17.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acrux Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11902780800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $118.22 Million | 11556.01% |
| Other Comprehensive Income | $9.04 Million | 883.38% |
| Total Equity | $1.02 Million | 100.00% |
Acrux Limited Competitors by Market Cap
The table below lists competitors of Acrux Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VIOL Co. Ltd
KQ:335890
|
$4.04 Million |
|
Stenocare AS
CO:STENO
|
$4.04 Million |
|
Semilux International Ltd. Ordinary Shares
NASDAQ:SELX
|
$4.04 Million |
|
URU METALS LTD
F:NVRA
|
$4.04 Million |
|
Marvel Biosciences Corp.
PINK:MBCOF
|
$4.03 Million |
|
Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
|
$4.03 Million |
|
Synertec Corporation Ltd
AU:SOP
|
$4.03 Million |
|
Digicontent Limited
NSE:DGCONTENT
|
$4.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acrux Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,276,000 to 1,023,000, a change of -2,253,000 (-68.8%).
- Net loss of 5,945,000 reduced equity.
- New share issuances of 3,376,000 increased equity.
- Other comprehensive income increased equity by 486,000.
- Other factors decreased equity by 170,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.95 Million | -581.13% |
| Share Issuances | $3.38 Million | +330.01% |
| Other Comprehensive Income | $486.00K | +47.51% |
| Other Changes | $-170.00K | -16.62% |
| Total Change | $- | -68.77% |
Book Value vs Market Value Analysis
This analysis compares Acrux Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.23x to 13.77x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-06-30 | $0.18 | $0.04 | x |
| 2003-06-30 | $0.12 | $0.04 | x |
| 2004-06-30 | $0.08 | $0.04 | x |
| 2005-06-30 | $0.24 | $0.04 | x |
| 2006-06-30 | $0.15 | $0.04 | x |
| 2007-06-30 | $0.13 | $0.04 | x |
| 2008-06-30 | $0.24 | $0.04 | x |
| 2009-06-30 | $0.20 | $0.04 | x |
| 2010-06-30 | $0.50 | $0.04 | x |
| 2011-06-30 | $0.28 | $0.04 | x |
| 2012-06-30 | $0.32 | $0.04 | x |
| 2013-06-30 | $0.28 | $0.04 | x |
| 2014-06-30 | $0.25 | $0.04 | x |
| 2015-06-30 | $0.24 | $0.04 | x |
| 2016-06-30 | $0.26 | $0.04 | x |
| 2017-06-30 | $0.26 | $0.04 | x |
| 2018-06-30 | $0.18 | $0.04 | x |
| 2019-06-30 | $0.13 | $0.04 | x |
| 2020-06-30 | $0.08 | $0.04 | x |
| 2021-06-30 | $0.08 | $0.04 | x |
| 2022-06-30 | $0.03 | $0.04 | x |
| 2023-06-30 | $0.03 | $0.04 | x |
| 2024-06-30 | $0.01 | $0.04 | x |
| 2025-06-30 | $0.00 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acrux Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -581.13%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -499.58%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 7.06x
- Recent ROE (-581.13%) is below the historical average (-38.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -17.99% | -574.45% | 0.03x | 1.05x | $-4.89 Million |
| 2003 | -0.09% | -1.34% | 0.06x | 1.10x | $-1.17 Million |
| 2004 | -0.04% | -0.09% | 0.33x | 1.16x | $-841.52K |
| 2005 | 0.08% | 0.88% | 0.09x | 1.05x | $-2.92 Million |
| 2006 | -48.29% | -1922.63% | 0.02x | 1.13x | $-12.00 Million |
| 2007 | -43.08% | -271.32% | 0.14x | 1.12x | $-9.68 Million |
| 2008 | -13.19% | -130.85% | 0.09x | 1.08x | $-8.84 Million |
| 2009 | -24.71% | -1187.08% | 0.02x | 1.12x | $-10.84 Million |
| 2010 | 57.85% | 84.79% | 0.66x | 1.04x | $38.51 Million |
| 2011 | 125.02% | 63.78% | 1.52x | 1.29x | $52.58 Million |
| 2012 | 13.92% | 84.02% | 0.15x | 1.10x | $2.08 Million |
| 2013 | 14.81% | 44.54% | 0.29x | 1.13x | $2.25 Million |
| 2014 | 66.50% | 52.41% | 1.00x | 1.27x | $23.76 Million |
| 2015 | 27.40% | 45.21% | 0.51x | 1.19x | $7.07 Million |
| 2016 | 29.58% | 46.35% | 0.52x | 1.22x | $8.59 Million |
| 2017 | -0.55% | -1.04% | 0.49x | 1.08x | $-4.64 Million |
| 2018 | -47.32% | -527.80% | 0.08x | 1.08x | $-17.18 Million |
| 2019 | -37.95% | -1319.33% | 0.03x | 1.11x | $-10.52 Million |
| 2020 | -73.71% | -755.87% | 0.07x | 1.39x | $-10.76 Million |
| 2021 | -68.37% | -944.58% | 0.06x | 1.26x | $-14.48 Million |
| 2022 | -108.18% | -572.08% | 0.12x | 1.57x | $-10.74 Million |
| 2023 | -8.79% | -9.06% | 0.63x | 1.53x | $-1.63 Million |
| 2024 | -177.05% | -113.93% | 0.57x | 2.74x | $-6.13 Million |
| 2025 | -581.13% | -499.58% | 0.16x | 7.06x | $-6.05 Million |
Industry Comparison
This section compares Acrux Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acrux Limited (ARUXF) | $1.02 Million | -17.99% | 6.06x | $4.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |